We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Blood Test Aids Early Detection of Rheumatoid Arthritis

By LabMedica International staff writers
Posted on 09 Mar 2015
A blood test that measures the levels of a certain protein can be used in conjunction with clinical assessments to assist with the diagnosis of rheumatoid arthritis is now available in North America.

Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disorder that primarily affects joints and it may result in deformed and painful joints, which can lead to loss of function. More...
The disease may also have signs and symptoms in organs other than joints.

The JOINTstat test (Augurex Life Science; Vancouver, BC, Canada) measures 14-3-3η (eta), a protein involved in joint damage that leads to debilitation in patients with RA, a disease that affects one out of every 100 Canadians. High levels of 14-3-3η protein indicate that the patient should be referred to a rheumatologist. JOINTstat has been evaluated in clinical studies in over 3,000 patients and has been available in the USA since late 2013.

Extracellular 14-3-3η protein is a potent ligand and activator of intracellular signaling pathways that lead to the upregulation of inflammation and joint damage factors involved in RA pathogenesis. A quantitative enzyme-linked immunosorbent assay is used to assess 14-3-3η protein levels. Studies have shown that when the test is positive, greater than 0.19 ng/mL, it provides a 5 to 50 times greater likelihood of having RA versus non-RA. At high levels of greater than 80 ng/mL is an indicator of RA that will lead to more joint damage over three years and at lower levels of less than 0.4 ng/mL or negative in RA diagnosed patients indicates a higher likelihood of response to RA therapy.

Walter Maksymowych, MD, FRCPC, a professor in the department of medicine, division of rheumatology at the University of Alberta (Edmonton, AB, Canada) said, “When diagnosed early, rheumatoid arthritis can be better managed with drug therapies, resulting in better outcomes by limiting disease progression. Current diagnostic tests are limited in their ability to catch the disease early. With the availability of JOINTstat in Canada, physicians now have the opportunity to treat rheumatoid arthritis early, prior to the onset of significant joint damage. This represents an important milestone towards the goal of personalized medicine.” The study was presented at the Canadian Rheumatology Association (CRA) Annual Scientific Meeting held February 4–7, 2015, in Québec City (QC, Canada).

Related Links:

Augurex Life Science
University of Alberta



Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Luteinizing Hormone Assay
DRG LH-Serum ELISA Kit
New
Malondialdehyde HPLC Test
Malondialdehyde in Serum/Plasma – HPLC
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Pathology

view channel
Image: AI-analyzed images from the FDM microscope show platelet clumps in motion (Photo courtesy of Hirose et al CC-BY-ND)

AI Microscope Spots Deadly Blood Clots Before They Strike

Platelets are small blood cells that act as emergency responders in the body, rushing to areas of injury to help stop bleeding by forming clots. However, sometimes platelets can overreact, leading to complications.... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.